Vitrakvi (larotrectinib)

Numéro de dossier de l’APP: 21598
État des négociations:
Active Negotiation
Indication(s):
For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.
Promoteur/fabricant:
Bayer Inc.
Numéro de projet de l’ACMTS:
PC0221-000
Lettre-contrat de l’APP:
Conclusion du processus de négociation:
Not Applicable